413 related articles for article (PubMed ID: 16515981)
1. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
2. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
4. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
[TBL] [Abstract][Full Text] [Related]
5. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
6. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
[TBL] [Abstract][Full Text] [Related]
7. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
8. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
9. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Grubb RL; Black A; Izmirlian G; Hickey TP; Pinsky PF; Mabie JE; Riley TL; Ragard LR; Prorok PC; Berg CD; Crawford ED; Church TR; Andriole GL;
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):748-51. PubMed ID: 19258472
[TBL] [Abstract][Full Text] [Related]
12. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
13. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
14. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
16. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
17. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
Harris CH; Dalkin BL; Martin E; Marx PC; Ahmann FR
J Urol; 1997 May; 157(5):1740-3. PubMed ID: 9112517
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen doubling time among Japanese men in an annual health screening program.
Terai A; Matsui Y; Ichioka K; Ohara H; Terada N; Yoshimura K
Int J Urol; 2004 Oct; 11(10):856-61. PubMed ID: 15479290
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
20. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
